03.05.2018Oculis raises CHF20 million and moves to SwitzerlandYou are hereNewsOculis raises CHF20 million and moves to Switzerland
Find an actor
ILMAC Lausanne 201803.10.2018ILMAC Lausanne is the new platform for the chemical & life sciences community. The event will take place on 3 and 4...
Alcon arrive à GenèveAlcon quitte Novartis et choisi le canton de Genève pour s'installer avec une équipe de 700 personnes.
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.